Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI could outsmart bacteria: a smarter way to choose antibiotics?

NCT ID NCT07762378

Disease control Sponsor: Instituto de Investigación Sanitaria Gregorio Marañón Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study tests whether a machine-learning system called iAST® can improve how doctors choose antibiotics for patients with pneumonia, urinary tract infections, or sepsis. The AI predicts which antibiotics are likely to work before standard lab results are available. Researchers will compare outcomes between patients treated before and after the AI tool is introduced, looking at recovery, complications, and survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A machine-learning decision support system (iAST®) that recommends antibiotics before lab results are known
What this could lead to
If effective, this AI tool could help doctors choose the right antibiotics faster, improving recovery and reducing complications in serious infections.
What could go wrong
The study is not randomized and compares before/after groups, so results may be influenced by other factors. The tool's recommendations may not always match the best treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 486 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients (aged ≥18 years) * Admitted to the Nephrology, Oncology or ICU wards * Diagnosis of sepsis, pneumonia and/or UTI * Empirical antibiotics prescribed Exclusion Criteria: * informed consent obtained \> 48 hours since the infection onset * beta-lactam allergy * infection syndrome other than sepsis, pneumonia or UTI * confirmed no-bacterial infection * death within the first 48 hours of inclusion or imminent risk of death at time of the inclusion * pregnancy and/or breastfeeding * inclusion in a clinical trial of antimicrobial treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bloodstream infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bacterial infectious disease with sepsis bacterial pneumonia bacterial urinary tract infection pneumonia Sepsis urinary tract infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bloodstream infection Pneumonia - bacterial Urinary tract infection bacterial

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.